← All trials
NCT06047379
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Feb 28, 2026
- Completion date
- Aug 31, 2026
- First posted
- Sep 21, 2023
- Last posted
- Dec 5, 2023
- Enrollment
- 134
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NeOnc TechnologiesLead sponsor
- NeOnc TechnologiesOfficial
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Astrocytoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Glioblastoma
- Melanoma
- Neoplasm Metastasis
- Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Carcinoma, Merkel Cell
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.